{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:44:44Z","timestamp":1791816284016,"version":"4.3.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hematologic toxicity is a major adverse event of temozolomide chemoradiotherapy for newly diagnosed glioblastoma. Although severe hematologic toxicity occurs in approximately 10% of patients, its impact on health-related quality of life (HRQoL) is unknown. This study evaluated the association between temozolomide-related hematologic toxicity and HRQoL in patients with newly diagnosed glioblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy and available HRQoL data from 3 clinical trials were included. Primary HRQoL outcomes were physical, social, and role functioning, pain, fatigue, nausea\/vomiting, and global health status. Severe hematologic toxicity was defined as grade 3-4 neutropenia, lymphopenia, thrombocytopenia, or anemia; febrile neutropenia; or prolonged (&amp;gt;30 days) grade 2 toxicity. Associations between severe hematologic toxicity and HRQoL were evaluated using linear mixed models. Clinical relevance was interpreted as glioma-specific minimally important difference thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1288 patients, 8% experienced severe hematologic toxicity during the concomitant phase, 6% during the maintenance and 1% during both. During the concomitant phase, severe hematologic toxicity was more frequent in females and in patients with MGMT promoter methylation. From baseline to week 6, global health mean scores declined by \u22128.52 points in patients with severe toxicity and \u22124.78 points in those without, with a non-significant difference (P\u2009=\u2009.24). Similar patterns were observed for physical, social, and role functioning. Symptom scales were numerically worse in severe toxicity but not significantly different. During the maintenance phase, differences were minor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Severe temozolomide-related hematologic toxicity showed no statistically significant association with impaired HRQoL, suggesting limited impact on patient-reported functioning and symptoms. Possible effects on psychological functioning should be examined further.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag224","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:34:12Z","timestamp":1788867252000},"source":"Crossref","is-referenced-by-count":0,"title":["Association between temozolomide-related hematologic toxicity and health-related quality of life in patients with newly diagnosed glioblastoma"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0289-9614","authenticated-orcid":false,"given":"Abigirl","family":"Machingura","sequence":"first","affiliation":[{"name":"European Organization for Research and Treatment of Cancer (EORTC) , Brussels,","place":["Belgium"]},{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-5392","authenticated-orcid":false,"given":"Johannes","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, University Hospital Bonn , Bonn,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-9616","authenticated-orcid":false,"given":"Johan A F","family":"Koekkoek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-9895","authenticated-orcid":false,"given":"Linda","family":"Dirven","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Oncology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-214X","authenticated-orcid":false,"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital & University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-3118","authenticated-orcid":false,"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University , Chicago, Illinois,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital & University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2531-0050","authenticated-orcid":false,"given":"Madeline","family":"Pe","sequence":"additional","affiliation":[{"name":"European Organization for Research and Treatment of Cancer (EORTC) , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9159-2761","authenticated-orcid":false,"given":"Thierry","family":"Gorlia","sequence":"additional","affiliation":[{"name":"European Organization for Research and Treatment of Cancer (EORTC) , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-4722","authenticated-orcid":false,"given":"Martin J B","family":"Taphoorn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-3278","authenticated-orcid":false,"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Hematology, University Hospital & University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-5089","authenticated-orcid":false,"given":"Clemens","family":"Seidel","sequence":"additional","affiliation":[{"name":"Department of Radiation-Oncology, University of Leipzig Medical Center , Leipzig,","place":["Germany"]},{"name":"Comprehensive Cancer Center Central Germany , Leipzig,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026101209463673600_noag224-B1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"2026101209463673600_noag224-B2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026101209463673600_noag224-B3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026101209463673600_noag224-B4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/neuonc\/noad038","article-title":"Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults","volume":"25","author":"Weller","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026101209463673600_noag224-B5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026101209463673600_noag224-B6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/neuonc\/noac070","article-title":"Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026101209463673600_noag224-B7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","article-title":"Health-related quality of life in patients with glioblastoma: a randomised controlled trial","volume":"6","author":"Taphoorn","year":"2005","journal-title":"Lancet Oncol"},{"key":"2026101209463673600_noag224-B8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026101209463673600_noag224-B9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/jnnp.2004.036186","article-title":"Facets and determinants of quality of life in patients with recurrent high grade glioma","volume":"76","author":"Giovagnoli","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026101209463673600_noag224-B10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026101209463673600_noag224-B11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026101209463673600_noag224-B12","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","article-title":"Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 phase III randomized trial","volume":"24","author":"Mirimanoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026101209463673600_noag224-B13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026101209463673600_noag224-B14","doi-asserted-by":"publisher","first-page":"iii98","DOI":"10.1093\/neuonc\/noz126.359","article-title":"P14.124 EORTC 1709\/CCTG CE.8: a phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma","volume":"21","author":"Roth","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026101209463673600_noag224-B15","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/S1470-2045(19)30796-X","article-title":"Glioma patient-reported outcome assessment in clinical care and research: a response assessment in neuro-oncology collaborative report","volume":"21","author":"Armstrong","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026101209463673600_noag224-B16","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"2026101209463673600_noag224-B17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/neuonc\/noab037","article-title":"Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients","volume":"23","author":"Dirven","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026101209463673600_noag224-B18","doi-asserted-by":"publisher","first-page":"pkz037","DOI":"10.1093\/jncics\/pkz037","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer","volume":"3","author":"Musoro","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"2026101209463673600_noag224-B19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026101209463673600_noag224-B20","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1080\/0284186X.2018.1492151","article-title":"Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials","volume":"57","author":"Kristensen","year":"2018","journal-title":"Acta Oncol"},{"key":"2026101209463673600_noag224-B21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/annonc\/mdv129","article-title":"The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)","volume":"26","author":"Al-Batran","year":"2015","journal-title":"Ann Oncol"},{"key":"2026101209463673600_noag224-B22","doi-asserted-by":"publisher","first-page":"vdac152","DOI":"10.1093\/noajnl\/vdac152","article-title":"Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG oncology\/RTOG 0825","volume":"4","author":"Scheurer","year":"2022","journal-title":"Neurooncol Adv"},{"key":"2026101209463673600_noag224-B23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11060-022-03944-6","article-title":"Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study","volume":"156","author":"Moitra","year":"2022","journal-title":"J Neurooncol"},{"key":"2026101209463673600_noag224-B24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1215\/15228517-2008-120","article-title":"Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors","volume":"11","author":"Armstrong","year":"2009","journal-title":"Neuro Oncol"},{"key":"2026101209463673600_noag224-B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11060-026-05474-x","article-title":"Clinical and genetic predictors of temozolomide-induced severe myelotoxicity in adult diffuse glioma: a case-control study","volume":"177","author":"Malhotra","year":"2026","journal-title":"J Neurooncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag224\/71000626\/noag224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag224\/71000626\/noag224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:46:46Z","timestamp":1791812806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag224\/8788457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag224","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"noag224"}}